1.85Open1.85Pre Close0 Volume25 Open Interest125.00Strike Price0.00Turnover222.90%IV47.43%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry1.85Extrinsic Value100Contract SizeAmericanOptions Type-0.0407Delta0.0009Gamma126.64Leverage Ratio-0.3295Theta-0.0036Rho-5.15Eff Leverage0.0376Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet